#begin document (nw/wsj/04/wsj_0463); part 000
nw/wsj/04/wsj_0463   0    0        Genentech    NNP         (TOP(S(NP*       -    -   -   -   (ORG*   (ARG0*        *           *   -
nw/wsj/04/wsj_0463   0    1             Inc.    NNP                  *)      -    -   -   -       *)       *)       *           *   -
nw/wsj/04/wsj_0463   0    2             said    VBD               (VP*      say  01   -   -       *      (V*)       *           *   -
nw/wsj/04/wsj_0463   0    3              the     DT     (SBAR(S(NP(NP*       -    -   -   -       *   (ARG1*   (ARG0*           *   -
nw/wsj/04/wsj_0463   0    4             West     JJ             (ADJP*       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0    5           German     JJ                  *)      -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0    6      distributor     NN                  *)      -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0    7               of     IN               (PP*       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0    8              its   PRP$            (NP(NP*       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0    9            heart     NN                  *       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   10             drug     NN                  *)      -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   11              TPA    NNP            (NP*))))      -    -   -   -       *        *        *)          *   -
nw/wsj/04/wsj_0463   0   12          reached    VBD               (VP*    reach  01   -   -       *        *      (V*)          *   -
nw/wsj/04/wsj_0463   0   13                a     DT               (NP*       -    -   -   -       *        *   (ARG1*           *   -
nw/wsj/04/wsj_0463   0   14            joint     JJ                  *       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   15        marketing     NN                  *       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   16        agreement     NN                  *)      -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   17             with     IN               (PP*       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   18                a     DT            (NP(NP*       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   19       subsidiary     NN                  *)      -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   20               of     IN               (PP*       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   21          Hoechst    NNP            (NP(NP*       -    -   -   -   (ORG*        *        *      (ARG0*   -
nw/wsj/04/wsj_0463   0   22               AG    NNP                  *)      -    -   -   -       *)       *        *           *)  -
nw/wsj/04/wsj_0463   0   23                ,      ,                  *       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   24            which    WDT        (SBAR(WHNP*)      -    -   -   -       *        *        *    (R-ARG0*)  -
nw/wsj/04/wsj_0463   0   25            makes    VBZ             (S(VP*     make  01   -   -       *        *        *         (V*)  -
nw/wsj/04/wsj_0463   0   26              the     DT            (NP(NP*       -    -   -   -       *        *        *      (ARG1*   -
nw/wsj/04/wsj_0463   0   27            rival     JJ                  *       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   28    anti-clotting     JJ                  *       -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   29            agent     NN                  *)      -    -   -   -       *        *        *           *   -
nw/wsj/04/wsj_0463   0   30    streptokinase    NNP   (NP*)))))))))))))      -    -   -   -       *        *)       *)          *)  -
nw/wsj/04/wsj_0463   0   31                .      .                 *))      -    -   -   -       *        *        *           *   -

nw/wsj/04/wsj_0463   0    0              The     DT         (TOP(S(NP*        -    -   -   -        *   (ARG0*        *        *   -
nw/wsj/04/wsj_0463   0    1    biotechnology     NN                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0    2          concern     NN                  *)       -    -   -   -        *        *)       *        *   -
nw/wsj/04/wsj_0463   0    3             said    VBD               (VP*       say  01   -   -        *      (V*)       *        *   -
nw/wsj/04/wsj_0463   0    4              the     DT     (SBAR(S(NP(NP*        -    -   -   -        *   (ARG1*   (ARG1*        *   -
nw/wsj/04/wsj_0463   0    5        agreement     NN                  *)       -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0    6          between     IN               (PP*        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0    7              its   PRP$         (NP(NP(NP*        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0    8         longtime     NN                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0    9             West     JJ             (ADJP*        -    -   -   -   (NORP*        *        *        *   -
nw/wsj/04/wsj_0463   0   10           German     JJ                  *)       -    -   -   -        *)       *        *        *   -
nw/wsj/04/wsj_0463   0   11      distributor     NN                  *)       -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   12                ,      ,                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   13       Boehringer    NNP            (NP(NP*        -    -   -   -    (ORG*        *        *        *   -
nw/wsj/04/wsj_0463   0   14               -    HYPH                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   15        Ingleheim    NNP                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   16               's    POS                  *)       -    -   -   -        *)       *        *        *   -
nw/wsj/04/wsj_0463   0   17              Dr.    NNP              (NML*        -    -   -   -    (ORG*        *        *        *   -
nw/wsj/04/wsj_0463   0   18             Karl    NNP                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   19           Thomae    NNP                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   20         G.m.b.H.    NNP                  *)       -    -   -   -        *)       *        *        *   -
nw/wsj/04/wsj_0463   0   21       subsidiary     NN                  *)       -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   22                ,      ,                  *)       -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   23              and     CC                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   24          Hoechst    NNP            (NP(NP*        -    -   -   -     (ORG)       *        *        *   -
nw/wsj/04/wsj_0463   0   25               's    POS                  *)       -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   26     Behringwerke    NNP                  *        -    -   -   -     (ORG)       *        *        *   -
nw/wsj/04/wsj_0463   0   27       subsidiary     NN               *))))       -    -   -   -        *        *        *)       *   -
nw/wsj/04/wsj_0463   0   28              was    VBD               (VP*        be  01   -   -        *        *      (V*)       *   -
nw/wsj/04/wsj_0463   0   29               an     DT               (NP*        -    -   -   -        *        *   (ARG2*        *   -
nw/wsj/04/wsj_0463   0   30          attempt     NN                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   31               to     TO             (S(VP*        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   32           expand     VB               (VP*    expand  01   -   -        *        *        *      (V*)  -
nw/wsj/04/wsj_0463   0   33              the     DT            (NP(NP*        -    -   -   -        *        *        *   (ARG1*   -
nw/wsj/04/wsj_0463   0   34           market     NN                  *)       -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   35              for     IN               (PP*        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   36            blood     NN        (NP(NP(NML*        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   37               -    HYPH                  *        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   38             clot     NN                  *)       -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   39            drugs    NNS                  *)       -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   40               in     IN               (PP*        -    -   -   -        *        *        *        *   -
nw/wsj/04/wsj_0463   0   41          general     NN   (NP*)))))))))))))       -    -   -   -        *        *)       *)       *)  -
nw/wsj/04/wsj_0463   0   42                .      .                 *))       -    -   -   -        *        *        *        *   -

nw/wsj/04/wsj_0463   0    0                A     DT    (TOP(S(NP*         -    -   -   -       *   (ARG0*        *         *   -
nw/wsj/04/wsj_0463   0    1        Genentech    NNP             *         -    -   -   -    (ORG)       *        *         *   -
nw/wsj/04/wsj_0463   0    2      spokeswoman     NN             *)        -    -   -   -       *        *)       *         *   -
nw/wsj/04/wsj_0463   0    3             said    VBD          (VP*        say  01   -   -       *      (V*)       *         *   -
nw/wsj/04/wsj_0463   0    4              the     DT   (SBAR(S(NP*         -    -   -   -       *   (ARG1*   (ARG0*         *   -
nw/wsj/04/wsj_0463   0    5        agreement     NN             *)        -    -   -   -       *        *        *)        *   -
nw/wsj/04/wsj_0463   0    6            calls    VBZ          (VP*       call  03   -   -       *        *      (V*)        *   -
nw/wsj/04/wsj_0463   0    7              for     IN        (SBAR*         -    -   -   -       *        *   (ARG1*         *   -
nw/wsj/04/wsj_0463   0    8          Hoechst    NNP        (S(NP*)        -    -   -   -    (ORG)       *        *    (ARG0*)  -
nw/wsj/04/wsj_0463   0    9               to     TO          (VP*         -    -   -   -       *        *        *         *   -
nw/wsj/04/wsj_0463   0   10          promote     VB       (VP(VP*    promote  02   -   -       *        *        *       (V*)  -
nw/wsj/04/wsj_0463   0   11              TPA    NNP          (NP*)        -    -   -   -       *        *        *    (ARG1*)  -
nw/wsj/04/wsj_0463   0   12              for     IN          (PP*         -    -   -   -       *        *        *    (ARG2*   -
nw/wsj/04/wsj_0463   0   13            heart     NN          (NP*         -    -   -   -       *        *        *         *   -
nw/wsj/04/wsj_0463   0   14         patients    NNS           *)))        -    -   -   -       *        *        *         *)  -
nw/wsj/04/wsj_0463   0   15              and     CC             *         -    -   -   -       *        *        *         *   -
nw/wsj/04/wsj_0463   0   16    streptokinase    NNP       (VP(NP*)        -    -   -   -       *        *        *         *   -
nw/wsj/04/wsj_0463   0   17              for     IN          (PP*         -    -   -   -       *        *        *         *   -
nw/wsj/04/wsj_0463   0   18            other     JJ          (NP*         -    -   -   -       *        *        *         *   -
nw/wsj/04/wsj_0463   0   19             clot     NN        (ADJP*         -    -   -   -       *        *        *         *   -
nw/wsj/04/wsj_0463   0   20               -    HYPH             *         -    -   -   -       *        *        *         *   -
nw/wsj/04/wsj_0463   0   21         reducing    VBG             *)        -    -   -   -       *        *        *         *   -
nw/wsj/04/wsj_0463   0   22         purposes    NNS   *)))))))))))        -    -   -   -       *        *)       *)        *   -
nw/wsj/04/wsj_0463   0   23                .      .            *))        -    -   -   -       *        *        *         *   -

#end document
